Revolutionary therapy offers hope for lupus patients, five enter remission

A groundbreaking medical therapy has offered significant hope to individuals suffering from lupus, with five patients achieving remission. The innovative treatment involves genetically modifying a patient's own immune cells to combat the autoimmune disease. Doctors involved in the study describe the results as a major advancement, suggesting that lupus could potentially be managed long-term or even cured in some cases.

The CAR-T therapy works by extracting a patient's immune cells, genetically engineering them in a laboratory to remove the cells responsible for attacking healthy tissues, and then reintroducing them into the body via infusion. This method, already showing success in treating certain cancers, has now demonstrated remarkable potential for autoimmune conditions.

The study, conducted by specialists at University College London Hospitals NHS Foundation Trust and University College London (UCL), involved nine patients with severe forms of lupus, many of whom suffered from lupus nephritis, a serious complication affecting the kidneys. Six patients received a lower dose of the CAR-T therapy, while three received a higher dose.

Remarkably, five of the six patients treated with the reduced dose entered remission within months and were monitored for an average of 11 months. The three patients on the higher dose have been observed for a shorter period, about three months, but doctors are optimistic they too will reach remission as monitoring continues. Blood tests indicated a rapid decline in disease activity, with some patients showing stabilized or improved kidney function.

Lupus is a chronic autoimmune disorder where the immune system mistakenly attacks the body's own healthy tissues, leading to inflammation and damage in organs like the kidneys, lungs, and heart. It affects an estimated five million people worldwide, predominantly women. Professor Karl Peggs, director of UCLH's Biomedical Research Centre, called the findings "truly groundbreaking" and stated they offer "new hope" to those living with lupus, while emphasizing the need for larger studies to confirm the outcomes.

“

These results are truly groundbreaking and offer new hope to people living with lupus.